Health Catalyst

Valuation Analysis

About the Company

Health Catalyst en bref

Health Catalyst (HCAT) is currently trading at 1,52 € with a market capitalization of 112 M €. The 52-week range spans from 0,83 € to 3,59 €; the current price is 57.8% below the yearly high. Year-over-year revenue growth stands at -10.9%.

💰 Dividende

Health Catalyst currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent Health Catalyst (HCAT) au consensus : Acheter. L'objectif de cours moyen est de 1,53 €, soit un potentiel de +0.57% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 0,87 € à 1,74 €.

Health Catalyst : la thèse d'investissement en détail

Health Catalyst (HCAT) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -10.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 11% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 223.97x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (11%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Health Catalyst?

Compare top-rated brokers — low fees, trusted providers, fully regulated.